About Vaxon Biotech
Vaxon Biotech is a Healthcare company based in Paris (France) founded in 2004. Therapeutic vaccines for multiple cancers are developed using cryptic peptides. Vaxon Biotech offers products and services including Vx-001 and Optimized Cryptic Peptides. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Vaxon Biotech is developing therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using its proprietary technology of optimised cryptic peptides. The company has a pipeline of tumour vaccines which cover major HLA-I to treat most cancer patients. Its drug pipeline include Vx-001 which is composed of two separate peptides: the native cryptic peptide ARG-Vx001 (TERT572) and its optimized variant TYR-Vx001 (TERT572Y) and being developed for the treatment of Non-small cell lung cancer (Phase 2b); Vx-006, a polypeptide composed of three optimized cryptic peptides derived from three different universal tumor antigens (MAGE, TERT, HER-2neu) for wide range of cancers (Phase 1); Vbx-016, a polypeptide composed of four optimized cryptic peptides derived from four different universal tumor antigens (CEA, MAGE, TERT and HER-2neu) (preclinical). Vx-001 obtained an orphan drug designation for NSCLC from EMA in Nov 2007 and from US FDA in Feb 2009.
- Headquarters Paris, France
- SectorsHealthcare
- Website vaxon-biotech.com
- Social LinkedIn
- Legal Name Vaxon Biotech
Products & Services of Vaxon Biotech
Vaxon Biotech offers a comprehensive portfolio of products and services, including Vx-001 and Optimized Cryptic Peptides.
Therapeutic vaccine for non-small-cell lung cancer treatment.
Technology to stimulate immune response against tumors.
Web traffic of Vaxon Biotech
Websites that share an audience with Vaxon Biotech (vaxon-biotech.com).
Websites whose visitors overlap most with Vaxon Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ab-science.com | 100% | 6.7K | #3,021,575 | View details | |
biotechbusiness.co.uk | biotechbusiness.co.uk | 86% | – | ||
| omeros.com | 86% | 15.6K | #1,695,799 | View details | |
| genvec.com | 53% | View details | |||
| dolcas-biotech.com | 52% | 2.1K | #7,699,716 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vaxon Biotech
Vaxon Biotech was founded in 2004.
Vaxon Biotech is headquartered in Paris, France.
Vaxon Biotech is developing therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using its proprietary technology of optimised cryptic peptides. The company has a pipeline of tumour vaccines which cover major HLA-I to treat most cancer patients. Its drug pipeline include Vx-001 which is composed of two separate peptides: the native cryptic peptide ARG-Vx001 (TERT572) and its optimized variant TYR-Vx001 (TERT572Y) and being developed for the treatment of Non-small cell lung cancer (Phase 2b); Vx-006, a polypeptide composed of three optimized cryptic peptides derived from three different universal tumor antigens (MAGE, TERT, HER-2neu) for wide range of cancers (Phase 1); Vbx-016, a polypeptide composed of four optimized cryptic peptides derived from four different universal tumor antigens (CEA, MAGE, TERT and HER-2neu) (preclinical). Vx-001 obtained an orphan drug designation for NSCLC from EMA in Nov 2007 and from US FDA in Feb 2009.
Vaxon Biotech offers Vx-001 and Optimized Cryptic Peptides.
Vaxon Biotech operates through Vaxon Biotech.